New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 15

Practice Patterns and Real Use of Epcoritamab and Glofitamab

, , ,

A panel of experts discuss the role of odronextamab.

Video content above is prompted by the following:

  • Briefly describe the role of odronextamab, after the FDA Complete Response Letter sent in March requiring active enrollment in the confirmatory portion of the Phase 3 OLYMPIA trial.